Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

X
Trial Profile

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemtabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BELLWAVE-003; MK-1026-003
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 27 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended as change in timeframe for primary end point is from 78months to 34 months.
    • 27 Sep 2022 Planned number of patients changed from 496 to 450.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top